As the year winds down, investors may be looking forward to 2023 and hoping for a better year in the stock market. Part of this growth is due to sales of consumables, which increased 53% year over year, outpacing revenue growth.
InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, is proud to announce the Health Canada license of the Forma-I to address the symptoms of dry eye disease due to Meibomian gland dysfunction (MGD). Forma-I is intended for use in the periorbital area and eyelids and relieves inflammation of meibomian glands and eye irritation.
InMode (NASDAQ: INMD) is a medical device company that provides its consumers with a wide range of treatments to help with contouring skin, treating acne, removing hair, and other aesthetic issues. InMode operates in an area of healthcare -- aesthetics -- that is proving to be strong amid inflation; in its most recent quarter (the period ended Sept. 30), the company reported revenue of $121.1 million, which was up 29% year over year.